HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 24, Issue 6, 2014, Pages 594-599

  Morgantini, C ^a,b   Meriwether, D ^c   Baldi, S ^a   Venturi, E ^a   Pinnola, S ^a   Wagner, A C ^c   Fogelman, A M ^c   Ferrannini, E ^a   Natali, A ^a   Reddy, S T ^c  

^a UNIVERSITY OF PISA   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; HDL; Lipid composition; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A; C REACTIVE PROTEIN; CHOLESTEROL; DICHLOROFLUORESCEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIOXIDANT; HYDROXYICOSATETRAENOIC ACID; LINOLEIC ACID;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CORONARY ARTERY CALCIUM SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY ACID OXIDATION; FEMALE; HUMAN; LIPID PEROXIDATION ASSAY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SAMPLING; VERY ELDERLY; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; COMPLICATION; DIABETIC ANGIOPATHIES; EPIDEMIOLOGY; ITALY; LIPID PEROXIDATION; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; UNIVERSITY HOSPITAL; UPREGULATION; VASCULAR CALCIFICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; ITALY; LINOLEIC ACIDS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION; VASCULAR CALCIFICATION;

EID: 84901490340     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.12.011     Document Type: Article

References (23)

1. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.
2. Morgantini C., Natali A., Boldrini B., Imaizumi S., Navab M., Fogelman A.M., et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 2011, 60:2617-2623.
3. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
4. Raterman H.G., Levels H., Voskuyl A.E., Lems W.F., Dijkmans B.A., Nurmohamed M.T. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013 Apr, 72(4):560-565.
5. Watanabe J., Charles-Schoeman C., Miao Y., Elashoff D., Lee Y.Y., Katselis G., et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012, 64:1828-1837.
6. Yu Y., Sheth N., Krishnamoorthy P., Saboury B., Raper A., Baer A., et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2012, 2:285-292.
7. Seraglia R., Sartore G., Marin R., Burlina S., Manzato E., Ragazzi E., et al. An effective and rapid determination by MALDI/TOF/TOF of methionine sulphoxide content of ApoA-I in type 2 diabetic patients. J Mass Spectrom 2013, 48:105-110.
8. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 2004, 95:764-772.
9. Moore R.E., Navab M., Millar J.S., Zimetti F., Hama S., Rothblat G.H., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005, 97:763-771.
10. Litvinov D., Mahini H., Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012, 4:523-532.
11. Connelly P.W., Draganov D., Maguire G.F. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic Biol Med 2005, 38:164-174.
12. Millar J.B., Rozengurt E. Arachidonic acid release by bombesin. A novel postreceptor target for heterologous mitogenic desensitization. J Biol Chem 1990, 265:19973-19979.
13. Di Marzo V. Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukot Essent Fatty Acids 1995, 53:239-254.
14. Spindler S.A., Clark K.S., Callewaert D.M., Reddy R.G. Role and detection of 9 and 13-hydroxyoctadecadienoic acids. Adv Exp Med Biol 1997, 407:477-478.
15. Morgantini C., Imaizumi S., Grijalva V., Navab M., Fogelman A.M., Reddy S.T. ApoA-i mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a mouse model of diabetes. Diabetes 2010.
16. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006, 23:579-593.
17. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001, 42:1308-1317.
18. Imaizumi S., Grijalva V., Navab M., Van Lenten B.J., Wagner A.C., Anantharamiah G.M., et al. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice. Drug Metab Lett 2010 Aug, 4(3):139-148.
19. McClelland R.L., Chung H., Detrano R., Post W., Kronmal R.A. Distribution of coronary artery calcium by race, gender, and age: results from the multi-ethnic study of atherosclerosis (MESA). Circulation 2006, 113:30-37.
20. O'Rourke R.A., Brundage B.H., Froelicher V.F., Greenland P., Grundy S.M., Hachamovitch R., et al. American College of Cardiology/American heart association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000, 36:326-340.
21. Assmann G., Schulte H., von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996, 77:1179-1184.
22. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B.
23. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 2001, 104:1108-1113.